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Summary 
Cyclosporin A (CsA) is a well-known immunosuppressive  agent that modulates immune tolerance 
in many ways. CsA can give rise to a state of long-term nonimmunosuppressed transplantation 
tolerance, but it can also aggravate autoimmune  diseases, and provoke specific  forms of antoimmunity. 
These effects, which are often paradoxical, remain largely unexplained. In this study, we investigated 
the effects of CsA on superantigen (superAg)-reactive peripheral T cells. The intravenous injection 
of either staphylococcal enterotoxin B (SEB), or Mls-1 a cells into Mls-1 b recipients,  causes long- 
term in vitro nonresponsiveness (anergy) and partial elimination of the peripheral T call receptor 
(TCR)  VB8+/CD4 +  and  -VB6+/CD4 +  T  cell  subsets,  respectively.  We  report  that  CsA 
markedly enhances the peripheral elimination of SEB- and Mls-la-reactive  T cells such that up 
to 90% of the targeted CD4 +/V3 subpopulations are deleted. The degree of deletion depends 
on the dose and the schedule of CsA administration, and the number of superAg injections. 
In situations where the extent of deletion is only moderate, we find that the remaining superAg- 
reactive T cells fail to develop anergy,  unlike the T cells of control superAg-immunized mice. 
Higher doses of CsA are required to enhance T cell deletion (t>25 mg/kg/d, i.p.) than to impair 
anergy induction (>16.25 mg/kg/d, i.p.).  In view of these results,  it appears that the degree of 
tolerance in CsA/superAg-treated mice depends on the balance between these opposing effects, 
i.e., enhancement of peripheral elimination versus the abrogation of anergy.  The possibility of 
enhancing or preventing immune tolerance with a drug may have important clinical implications. 
C 
Yclosporin  A  (CsA) 1 is  a potent immunosuppressive 
agent  used  clinically  to  control  allograft  rejection, 
GVHD, and some autoimmune diseases (1). It is well accepted 
that the principal inhibitory action of CsA is the result of 
impaired lymphokine production by T cells, especially IL2 
(2-4).  In rats,  a form of long-term nonimmunosuppressed 
tolerance to allografts can be induced by a short course of 
CsA treatment (5, 6). The underlying mechanism is not well 
understood, but may depend on the generation of antigen- 
specific suppressor cells (5, 7). Paradoxically, in some circum- 
stances, CsA treatment can have detrimental effects, which 
include the induction of autoimmune diseases and syngeneic 
GVHD (reviewed in reference 8). It has been suggested that 
CsA induces syngeneic GVHD by blocking intrathymic donal 
deletion (9, 10). However, our results (11) and those of Bryson 
et al. (12) do not support this interpretation. Alternatively, 
CsA could affect tolerance by acting on peripheral T  cells. 
1 Abbreviations used in this paper: CsA, cyclosporin A; SE, staphylococcal 
enterotoxin; Tx,  thymectomized. 
In this study, we analyzed the effects of CsA therapy on the 
peripheral tolerance induced by superantigens (superAgs). Two 
superAgs were used, staphylococcal enterotoxin B (SEB) and 
Mls-1 a (a product of the intrinsic mouse mammary tumor 
virus 7 [MMTV-7])  (13), which stimulate TCR V~8 + and 
TCR VB6 +/CD4 § T cells, respectively (14, 15). These su- 
perAgs are known to cause both a partial elimination and 
a long-term in vitro anergy in their targeted T cell subpopu- 
lations (16-20).  We found that superAg recognition during 
the course of CsA treatment leads to a considerable enhance- 
ment of the peripheral elimination of the reactive T  cells. 
This elimination process is superAg specific. With protocols 
that provoke an extensive elimination of superAg-reactive T 
cells, the proliferative responses to these antigens in vitro are 
very low.  In contrast,  CsA abrogates  the development of 
anergy, which usually occurs after injection of these superAgs. 
The latter effect is only apparent when sufficient numbers 
of undeleted T  cells remain after CsA/superAg treatment. 
Relatively low doses of CsA could inhibit anergy induction, 
while higher doses were required to enhance T cell deletion. 
The blockage of anergy by CsA may be of importance in 
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nomena. Based on our results, we postulate that CsA can 
induce a state of tolerance by provoking antigen-specific  T 
cell elimination, but can sometimes paradoxically increase re- 
sponses  by preventing anergy induction. 
Materials and Methods 
Mice.  BALB/c  mice (H-2  o, Mls-1  b, Mls-2  ~, Lyt-l.2, Lyt-2.2) 
and DBA/2 mice (H-2  d, MIs-P,  Mls-2', Lyt-l.1, Lyt-2.1) were 
purchased from Charles River Laboratory (St. Constant, Quebec, 
Canada), and C3H/HeJ mice (H-2  k, Mls-1  b, Mls-2  ~) were from 
The Jackson Laboratory (Bar Harbor, ME). Adult BALB/c mice 
(4-6 wk old) were thymectomized in our facility as described (21) 
and rested for 7 d before the onset of treatments. All the experi- 
ments were performed in female mice. 
mAbs and Reagents.  PE-conjugated anti-CD4, PE-conjugated 
anti-CD8, anti-Lyt-l.1,  anti-Lyt-2.1,  and anti-Thy-l.2  were purchased 
from Cedarlane Laboratories (Hornby, Canada). The following 
mAbs were produced as culture supernatants and purified by pro- 
tein G (Pharmacia, Montreal, Quebec, Canada) aflfinity  chroma- 
tography: anti-VB6 (44-22-1 hybridoma; 22), anti-VB8.1-8.2 (KJ16 
hybridoma; 23), anti-V/~8.1-8.2-8.3 (F23.1 hybtidoma; 24), anti- 
V~14 (14.2 hybridoma; 25), and anti-TCR-ce/~ (H57-579  hy- 
bridoma; 26). For flow cytometry analysis  the purified mAbs were 
directly  conjugated to FITC. CsA was a kind gift of  Sandoz (Dorval, 
Canada). SEA was purchased from Toxin Technology (Sarasota, 
FL) and SEB from was purchased from Sigma Chemical Co. (St. 
Louis, MO). 
SuperAg Immunization and CsA Treatments.  SuperAg  immuni- 
zations were performed by tail vein injections of either 107 Mls- 
P+  splenocytes (RBC depleted), or 50-100 #g of SEB. Cells or 
SEB were injected in a volume of 0.25 ml of PBS. The day of su- 
perAg injection was considered  day 0 of  our experiments. CsA was 
suspended in olive oil (OO) (20 mg/ml) and given intraperitoneally 
at a dose of 50 mg/kg/d, unless otherwise indicated. CsA was ad- 
ministered daily starting 1 d before superAg immunization (day 
-1) and continued until the day the mice were killed, unless other- 
wise indicated.  Control groups included  untreated mice, CsA-treated 
mice (no  superAg),  superAg-immunized mice (no  CsA), and 
superAg- and diluent (OO)-treated  mice. In control mice, CsA 
and/or diluent were administered in the same dose and/or volume 
as in the experimental groups. 
Flow Cytometry Analysis.  For two-color flow cytometry anal- 
ysis, LN cells (pooled cervical, axillary, para-aortic, and mesenteric 
LN) were stained with either PE-anti-CD4 or PE-anti-CDS, and 
with one of the FITC-labeled-anti-V/3  mAbs mentioned above. One- 
color flow cytometry analysis was performed with FITC-labeled 
mAbs only. Briefly, 5  x  10  s LN cells were incubated with PE- 
conjugated mAb for 15 min at 4~  then washed three times with 
PBS containing 1% FCS (Gibco, Burlington, Canada) and then 
incubated in the same conditions with the second FITC-labeled- 
anti-V/3 mAb. Propidium iodide (Sigma Chemical Co.) was added 
after the last wash. Dead cells were excluded based on propidium 
iodide staining and forward scatter. In each sample, 104 cells were 
analyzed on a FACScan  |  (Becton Dickinson & Co., Missisauga, 
Canada) flow cytometer, and results were plotted on a logarithmic 
scale. In  some experiments spleen cells were analyzed. Before 
staining, spleens cells (RBC depleted) were depleted of B cells by 
two rounds of sequential  J11.D2 mAb and complement treatment, 
performed as we have previously described (27). After depletion 
of dead cells on a lymphocyte-M gradient (Cedarlane Laborato- 
ties), spleen cells were stained and analyzed as described above for 
LN cells. 
In Vitro Proliferative Assays.  LN cells were cultured in 96-well 
flat-bottomed plates (Gibco Laboratories, Grand Island, NY) in 
quadruplates at 5  x  10  s ceUs/weU with either: (a) for SEB stim- 
ulation, with l& syngeneic irradiated (2,000 tad) splenocytes of 
untreated BALB/c mice and 10 #g/ml of SEB, or 1 #g/ml of SEA 
as a control; or (b) for MIs-P experiments, with 106 irradiated 
(1,000 tad) DBA/2 splenocytes  or irradiated (1,000 tad) allogeneic 
C3H/HeJ  (H-2  k,  Mls-1  b)  splenocytes. Cells were cultured  in 
RPMI 1640 (Gibco Laboratories)  containing 10% FCS, t-glutamine, 
5  x  10 -s  M  2-ME, and  antibiotics. Cells were pulsed with 
[3H]thymidine (ICN, Montreal, Canada) at day 3 of culture and 
harvested on day 4, unless otherwise indicated. Days  in culture refer 
to the day that the cells were harvested. In all cases, the cells were 
harvested after an 18-h incubation with [3H]thymidine.  In the case 
of stimulation with either SEA or SEB, Acpm = cmp experimental 
-  cpm control (no superAg). In the case of Mls-1  ~  or MLC stim- 
ulation, Acpm = clam  experimental -  cpm with syngeneic  stimu- 
lator cells. 
Results 
Enhanced Elimination  of superAg-reactive T  Cells in  CsA/ 
superAg-treated Mice.  When injected to an appropriate re- 
cipient, Mls-P + cells and SEB induce a partial elimination 
of the specific superAg-reactive  T  cells (19, 20, and Figs.  1 
and 2). We find that the elimination of superAg-reactive  T 
cells is markedly augmented by CsA administration. As shown 
in Table 1 and Figure 1, a-d, the frequency of CD4 +/V/~6 + 
T cells (reactive to Mls-1 a) in Mls-1 b recipients treated with 
CsA (50 mg/kg/d) decreases to <20% of the original values 
in BALB/c mice. The CD4 +/V/~8.1 + T cells, another Mls- 
1a-reactive  subset,  may  also  be  affected  by  CsA/Mls-P- 
treatment,  since  there  was  a  partial  decrease  in  KJ16 + 
(V/~8.1+/VB8.2+)/CD4 +  T  cell  population  (data  not 
shown). The loss of CD4+/V/36 + T  cells in CsA/Mls-1 ~- 
treated mice represents a 3.6-fold greater deletion, when com- 
pared with the control Mls-P-immunized (non-CsA-treated) 
groups (Table 1). The deletion is specific since the frequency 
of CD4+/V/~14 + T  cell (which do not react to Mls-1 a an- 
tigen) remained relatively unchanged. The enhanced deletion 
of CD4 +/V/~6 + T cells can be observed in both the spleen 
and LN of treated mice (Table 1). Generally, the CsA/Mls- 
l~-induced elimination is completed by day 7 postimmuni- 
zation (data not shown). Comparable results were obtained 
in CsA-treated CBA/CaJ (Mls-1  b) mice injected with CBA/J 
(Mls-1 ~) spleen  cells (data not shown). 
A CsA-enhanced T  cell elimination process was also ob- 
served in SEB-immunized mice. A  single injection of SEB 
after the initiation of CsA therapy (50 mg/kg/d) caused  a 
rapid decline in the numbers of the reactive  CD4 +/VB8 + 
T  cells, as demonstrated in Fig. 1, e-h,  and Table 2, unlike 
in the SEB-immunized control animals.  This early decline 
was apparent at day 3 (Table 2),  and was observed  within 
36 h post-SEB  immunization (data not shown). However, 
with only one SEB injection, CsA did not greatly enhance 
the deletion observed at days 12 and 30 (Table 2). When a 
second injection of SEB (SEBx2)  was performed at day 7, 
38  Cyclosporin  A Enhances T Cell Deletion and Inhibits Anergy Induction o 
0 
..I 
o 
0 
Untreated  a 
I 
I 
Untreated 
I 
15,0g  I  IS.It 
I 
,  %r.,,:.  ,  .......  i  ........ 
CsA  d  14  b 
I 
I 
Loo 
CsA  d  3 
J 
! 
--.l.  ,,, 
ff,~':.  #  "  '~ '." 
Log 
MIs-1 a  d  14 
I 
I 
~i.  ....... 
v~6 
SEB  xl  d  3 
i 
[ 
| 
I, 
:2 s  .2_ ....... 
w 
........  i  ....... 
v~8 
CsA/MIs4"  d  14 
d 
65,~  I  o.gt 
I 
I 
CsA/SEB  xl  d  3 
t$.~  I  6,~ 
I 
-."-i.:,,.i'" , .......  ,  ,  .~ .... 
Figure 1.  Enhanced elimination 
of superAg-reactive  T cells in CsA/ 
superAg-treated mice. Day 0 refers 
to the day of superAg (Mls-l" or 
SEB) injection. CsA (50 mg/kg/d) 
was administered from day  -1 of 
the experiments until either day 3 
or 14 as indicated. Histograms show 
two-color  flow cytometry analysis 
of BALB/c LN cells of untreated 
mice (a and e); CsA-treated control 
mice (b and J); Mls-la-immunized 
mice (c); CsA-treated and Mls-P- 
immunized (CsA/MIs-1  a) mice (d); 
SEB-immunized mice (g); and CsA- 
treated SEB-immunized (CsAISEB) 
mice (h). Staining was performed 
with CD4-PE and either anti-Va6- 
FITC (44-22-1 mAb) or anti-V08- 
FITC (F23.1, anti-Va8.1, 8.2,  8.3 
mAb). 10,000 cells were analyzed 
in each histogram  and results are 
plotted on a logarithmic  scale. 
Table  1.  CsA Enhances Elimination  of Mls-Y-reactive  CD4*/V#6 §  T  Cells in Mls-P.treated Mice 
V06 among CD4* 
Mls-P  Mls-P  CsA 
donor  recipient  treatment  day 0*  day 3  day 14  day 28 
Vo6  among CD8 
day 0*  day 28 
DBA/2  BALB/c 
DBA/2  BALB/c 
-  9.9  _+  0.5  5.2  +  0.6  5.3  -+  0.3 
(10.3  +_  0.7)  (7.1  +_  0.8) 
+  10.2  +_  0.5  4.3  _+  0.2  1.7  _+  0.1 
(10.4  +_  0.2)  (2.4  +  0.9) 
+s  3.3  -+  0.2 
(interrupted) 
6.2  +  0.8  11.9  +  1.2  11.3  +  1.3 
1.7  _+  0.2  11.0  +  0.9  10.7  _+  1.4 
Val4  among CD4 
day 0*  day 3  day 14  day 28 
-  9.4  _+  0.2  9.5  +  0.3  10.3  -+  0.4 
(9.8  _+  0.1)  (9.9  +  0.2) 
+  8.9  +  0.5  9.9  +  0.2  10.4  _+  0.2 
(9.9  _+  0.0)  (10.9  _+  0.1) 
+s  10.7  _+  0.0 
(interrupted) 
V~14  among CD8 
day 0*  day 28 
9.9  _+  0.7  4.0  _+  0.3  4.5  +  0.4 
10.0  _+  0.5  4.0  +  0.5  4.8  _+  0.2 
* Day 0 represents the day of superAg immunization. Mice received either  no CsA (-)  or a daily injection of 50 mg/kg of CsA beginning on 
day  -  1, until either day 3, 14, or 28 as indicated. LN cells were analyzed by two-color flow cytometry (see Fig. 1). Values in parentheses represent 
analysis of B cell-depleted  spleen cells. 
t These mice were not injected with Mls-1  a cells. T cell frequencies for CsA-treated control mice are expressed as the mean for all CsA-treated con- 
trol groups (i.e., mice were injected with CsA from day  -  1 to either day 3,  14, or 28). V~6* and Va14 + T cell frequencies were closely similar 
in these three  groups. 
s CsA was administered  on day  -  1 and days 2-14 (i.e.,  a 2-d interruption of CsA treatment). 
39  Vanier and Prud'homme Table  2.  CsA Enhances Elimination of Vs8 + T  Cells in SEB-treated Mice 
SEB-reactive Va8  subset* 
Vo8 among CD4  Va8 among CD8 
BALB/c 
SEB  injected  CsA treatment  day 0*  day 3  day 12  day 30  day 0*  day 30 
xl 
x2 
xl 
x2 
-  23.7  _+  0.5  24.8  _  0.9  13.2  -+  0.3  13.4  _+  0.5  41.6  _+  1.6  35.0  _+  1.4 
+  24.2  _+  0.9  11.9  _+  0.8  11.6  _+  0.6  8.9  +  0.9  40.1  _+  2.0  16.3  +  2.5 
+  (stopped day 20)s  22.9  _+  1.1  8.5  +  0.3  15.9  _+  1.8 
-  12.4  _+  0.2  12.7  _+  0.3  18.3  _+  0.3 
+  6.5  _+  0.3  5.2  _+  0.2  14.2  _+  0.6 
Control Va6  subset 
Va6 among CD4  Va6 among CD8 
day 0*  day 3  day 12  day 30  day 0*  day 30 
-  9.9  _+  0.6  9.5  _+  0.4  12.2  _+  0.2  11.9  +  1.1  11.5  ___  1.1  13.1  _+  0.7 
+  10.2  +_  0.2  13.0  +  1.2  t3.8  _+  0.6  11.5  _+  0.3  11.6  •  0.6  14.9  _+  0.8 
+  (stopped  day 20)s  9.8  _+  0.4  10.5  _+  0.6  15.0  _+  0.2 
-  12.6  _+  0.1  12.1  _+  0.9  14.4  _+  1.1 
+  13.7  _+  1.0  14.3  _+  1.0  15.2  _+  2.1 
* Day 0 represents the day of the first super Ag immunization. Mice received one (xl) or two (x2) injections of 100/xg of SEB. The second injection 
of SEB was performed at day 7. Mice received either no CsA ( - ) or 50 mg/kg of CsA daily from day  -  1, until either day 3, 12, or 30 as indicated. 
LN cells were analyzed by two-color flow cytometry (see Fig. 1).  Va8 + T  cells were  detected with the F23.1 mAb (anti-Va8.1,  8.2,  8.3). 
* These mice were not injected with SEB. T cell frequencies for CsA-treated control (non-SEB-injected) mice represent the mean of the three groups 
injected with CsA from day  -1 to either  day 3,  12, or 30.  Va8 + and Va6 + T  cell frequencies were  closely similar in these three groups. 
S These mice received CsA from day  -  1 to day 20. 
the  long-term  deletion of CD4+/VB8 +  T  cells  became 
clearly more pronounced in CsA-treated  than in non-CsA- 
treated mice (Table 2). Multiple additional injections of SEB 
in  CsA-treated mice greatly enhanced the elimination of 
CD4 +/VB8 + T cells, such that their frequency decreased to 
1.8%  (Fig.  2).  This represents <10%  of the frequency of 
CD4 +/V~8 + T  cells normally found in BALB/c mice. In 
mice that received a single injection of SEB, CsA provoked 
the loss of approximately half of the CD8 +/VB8 + T cells, 
while there was only a small reduction in the numbers of 
these cells in control mice (Table 2). Unlike CD4 +/VB8  + 
T cells, the elimination of CD8 +/V[38 +  T  cells was not fur- 
ther augmented by multiple injections of SEB (Table 2 and 
data not shown). The CsA/SEB elimination process is superAg 
specific, as shown by the unaltered (or slightly increased) fre- 
quency of CD4 +/V/~6 + and CD8 +/V[36 + T cells (Table 2). 
Effect of CsA Dose on T  Cell Deletion.  SuperAg-induced 
T  cell deletion was enhanced in mice injected with CsA at 
doses  of 25  mg/kg/d,  and  even  more  so  at  doses  of  50 
mg/kg/d,  but not in mice injected with lower  CsA doses 
or diluent (OO) (Fig. 3). While CsA enhanced T  cell dele- 
tion,  it inhibited the development of anergy that  was  ob- 
served in control mice (see below under in vitro stimulation 
assays). 
CsA/superAg-induced Elimination in Thymectomized (Tx) Mice 
and the Effects of CSA  Treatment Termination.  To determine 
if the T  cell deletion was a peripheral event, adult BALB/c 
mice were Tx 7 d  before CsA treatment and/or Mls-1  aim- 
Table  3.  Enhanced CD4+/VB6 § T  Cell Elimination by CsA 
Treatment in the LN of Thymectomized Mls-l"-immunized 
BALB/c 
Va6 among CD4 §  cells 
CsA 
treatment*  day 0*  day 3  day 14  day 28 
-  10.6  _+  0.2  6.4_+  0.3  6.5  _+  0.0  6.5  _+  0.5 
Continuous  10.3  _+  0.4  6.4  _+  0.1  2.2  -+  0.1  2.4  +  0.2 
Stopped at 
day 20s  10.2  _+  0.2  -  -  2.2  _+  0.4 
* Mice received either  no CsA ( - ) or 50 mg/kg/d of CsA from day 
-1, up until either  day 3,  14, or 28 as indicated. 
* Mice not immunized with Mls-l' cells. 
S These mice received CsA from day  -  1 to day 20. 
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Figure 2.  Marked enhancement  of CD4 +/V~8 + T cell deletion with 
multiple injections  of SEB in CsA-treated mice. Single-color histograms 
represent  the relative numbers  of gated LN CD4 + cells (y-axis) stained 
with FITC-conjugated anti-V~8.1-8.2 (KJ16) mAb (x-axis). SEB (50/~g) 
was injected intravenously either once (SEBxl) or every 4 d up to five times 
(SEBx5) and the mice were killed 4 d after the last injection.  The histo- 
grams on the left are from non-CsA-treated mice, while those on the right 
are from CsA-treated mice. CsA treatment (50 mg/kg/d) was begun 1 d 
before the first SEB injection and continued until the day at which the 
mice were killed.  Representative  results are shown. 
munization. As shown in Table 3, the extent of elimination 
of CD4 +/V~6 + T cells in CsA/Mls-l~-treated  Tx mice was 
equivalent  to that  observed  in the euthymic groups. 
When CsA treatment was stopped for 8 d in CsA/Mls- 
P-treated Tx mice (Table 3) or 10 d in euthymic CsA/SEB- 
O 
s 
MIs-l*-immunized day 14 
11101  T  •  T 
~..  ,/4  .... ￿9  .... ; 
1 
0  i  i  L  i 
OO  6.25  12.5  25  50 
$EBx2-1mmunized day 12 
8 
5 
/  i  L  ;  ; 
OO  6.25  12.5  25  SO 
Mle-18-immunized day t4 
170 
150  T 
150  I 
140  ~ 
1so  /i\ 
12o  /  ~\ 
~  110  T/  \ 
,oo  1/  \ 
90 
.o  ~  \h 
d  6O  50  .  .  4O  ~_  c3.1.,a  -  _  30 / 
2~  '  lO 
0  L  i  i 
OO  6.25  12.5  25  50 
SEBx2-1mmunized day 12 
380 
-~ f  r  ~  320  ,~1,  SEA 
300  ,  ",  T 
250~-"  ~  ~  "" 
260 ~ 
240 
220 
200 
150 
150 
t40 
120 
100 
80 
80 
40 
2O 
0 
OO  6.25  12.5  25  50 
CsA (mg/kgld) 
Figure 3.  Effects of CsA dose on LN T cell numbers  and in vitro re- 
sponses to superAgs. BALB/c mice were injected with either Mls-l~ cells 
or SEBx2. Immunizations and analyses were performed  as described in 
Tables 1 and 2. Mice were treated  with OO, or various  doses of CsA, 
from day  -1 to either day 12 (SEB-immunized  mice) or to day 14 (Mls- 
l~-injected mice). (A) Va6 + (A) and V~14 + (A) T cell numbers in Mls- 
l~-immunized mice; (B) VB8 + ([]) and V~6 + (IJ) T cell numbers in SEB- 
injected mice; (C) proliferative responses of LN cells to either DBA/2(H- 
2  a, Mls-l') (A) or C3H/HeJ (H-2  k,  Mls-1  b) (A) irradiated  stimulator 
cells, in Mls-l"-immunized mice; (D) proliferative responses of LN cells 
to either SEB ([]) or SEA (I), in SEB-immunized  mice. Results  repre- 
sent either percent  T call numbers  _+  SEM, among CD4 + cells (A and 
B), or A  cpm  •  SEM (C and D). Three to five mice were analyzed in 
each group. 
treated  mice (Table 2), we observed no change in superAg- 
reactive T cell frequency. Thus, withdrawal of CsA does not 
result in a rapid increase of superAg-reactive T cell numbers. 
T Cell Marker Analysis of  LN and Spleen Cells.  The reduc- 
tion of superAg-reactive T cells that we observed could have 
been secondary to either  deletion or to downregulation of 
the TCK.  In addition,  in the Mls-la-injected  groups (i.e., 
Mls-1  ~ alone or CsA/Mls-P-treated mice), there might have 
been an expansion of donor T cells, which would reduce the 
relative frequency of the host V3 subpopulations.  To answer 
these questions,  we analyzed the expression of several T cell 
markers in these mice. We found that the LN of CsA/Mls- 
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Group*  Va6+/CD4 +*  Va14+/CD4 §  TCR-c~/B +s  CD4+/CD8 +*  Thy-l.2 +*  Lyt-l.1 +s  Lyt-2.1 +s 
Untreated  6.0  _+  0.1  5.2  _+  0.3  74.4  +  0.2  73.6  +  0.3  75.2  _+  0.7  0.0  +_ 0.1  0.0  _+  0.0 
(0.0  +-  0.0)  (0.0  _+  0.0) 
CsA  5.9  _+  0.2  4.8  +  0.1  73.7  _  0.4  71.8  ,+  0.8  72.9  __  1.0  0.0  -+  0.0  0.0  _+  0.0 
(0.2  .+  0.2)  (0.2  ,+  0.1) 
Mls-P  3.4  _+  0.3  5.6  _+  0.6  75.3  ,+  0.5  75.8  ,+  0.1  74.7  _+  0.9  0.0  _+  0.1  0.0  _+  0.0 
(0.0  ,+  0.0)  (0.1  _+  0.1) 
CsA/Mls-I'  0.7  _+  0.2  5.2  +  0.3  67.9  .+  0.4  66.4  ,+  0.5  65.8  _+  1.2  0.0  _+  0.3  0.1  _+  0.3 
(0.0  .+  0.0)  (0.1  .+  0.2) 
* The groups are  the same at  those  described  in Fig.  1. 
* V~6+/CD4* cells and V~14+/CD4 + cells were enumerated  by two-color flow cytometry with CD4-PE and either anti V/~6-FITC  or anti-V/~14 
FITC. TCR-c~/~8  + and Thy-l.2 + cells were analyzed by one-color staining.  CD4 +/CD8 + represents the sum of CD4 + and CD8 + T cells analyzed 
in two colors.  Positive  cells are expressed as a percent  of total LN cell numbers  _+  SEM. 
S DBA/2 (donor)  cells are Lyt-l.1 + and  Lyt-2.1 +.  BALB/c (recipient)  cells are Lyt-l.2 + and Lyt-2.2 +.  In DBA/2 spleens a mean of 27.5%  of 
cells were Lyt-l.l+, and a mean of 13.5%  of cells were Lyt-2.1 + (data not shown).  Values in parentheses  represent  cell numbers  in B cell-depleted 
BALB/c (recipient)  spleen cells. 
P-treated mice had closely similar frequencies of cells ex- 
pressing either Thy-1, TCR-od~8,  or CD4  +  CD8  (Table 
4). Thus, it seems unlikely that there were significant numbers 
of T cells bearing conventional T cell markers but that they 
were negative for the TCR due to downregulation. Moreover, 
in  both  Mls-1 a-  and  SEB-treated groups,  no variation  in 
TCR intensity was detected in the superAg-reactive T  cell 
populations  (Figs.  1 and 2). 
In Mls-la-treated BALB/c mice the analysis of Lyt-1 and 
Lyt-2 alleles in the spleen (depleted of B cells by JllD2 and 
complement treatment) or the LN revealed that virtually all 
T lymphocytes were of host origin (Table 4). Consequently, 
non-V/~6  expressing  donor  T  cells  could  not  have  been 
replacing or diluting host T  cells. 
In Vitro Stimulation Assays.  Intravenous injection of Mls-1  '+ 
cells or SEB results in a state of anergy (proliferative non- 
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Figure 4.  Inhibition of SuperAg-induced  clonal anergy by CsA. (,4) The proliferative responses of the LN cells of BALB/c mice with SEB (open 
Mrs) or SEA (hatched bars) in vitro stimulation (cells harvested at day 4 of culture).  Mice were treated with CsA and SEB as explained in the legend 
to Fig. 2. R~sults represent the mean cpm _+  SEM (four to five mice in each group). (B) The in vitro proliferative responses of the LN cells of BALB/c 
mice treated with CsA and Mls-1, cell injections  as explained in the legend to Fig. 1. LN cells were stimulated  either with irradiated DBA/2 (H-2  d, 
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Figure 5.  Kinetics  of the peak proliferative  responses  in mice  immunized 
with superAg and/or CsA treated. The groups of mice presented here are 
the same as in Fig. 4. (2'1) LN cells of BALB/c mice were stimulated with 
SEB in vitro. The results represent the mean Acpm _+ SEM. (B) LN cells 
of BALB/c (H-2  a, Mls-1  b) mice (treated as indicated) were stimulated with 
DBA/2 (H-2  a, Mls-l~) irradiated spleen cells. The results represent the 
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responsiveness) when T  cells are challenged with the same 
antigen in vitro (16-18). As shown in Fig. 4 A, the T  cells 
of mice injected with SEB once (SEBxl) or five times (SEBx5) 
are strongly anergic, while responses to SEA are unchanged. 
The development of anergy was not observed when CsA (50 
mg/kg/d) was given in SEBxl-immunized mice (Fig.  4 A). 
The proliferative capacity to SEB remained comparable with 
untreated mice (Pig. 4 A). However, the elimination of SEB- 
reactive T  cells  was much more extensive in  CsA/SEBx5- 
treated mice, and in that case the SEB-stimulated prolifera- 
tion was drastically reduced (Fig. 4 A). Presumably, the latter 
low responses were due to the extensive T  cell elimination. 
The inhibition of anergy induction was apparent at CsA 
doses as low as 6.25 mg/kg/d,  although higher doses were 
more effective (Fig. 3). It is noteworthy that mice injected 
with 6.25 or 12.5 mg/kg/d of CsA did not have enhanced 
T  cell deletion (Fig. 3). In mice injected with 50 mg/kg/d 
of CsA, the blockage of anergy induction after Mls-1  ' treat- 
ment  was  difficult  to  assess,  because these mice  had  low 
numbers of CD4+/V/~6 + cells  (Table  1,  Fig.  3).  The low 
proliferative  responses  observed  with  MIs-P  stimulation 
(Fig.  4 b) could be secondary to the deletion event as well 
as to delayed onset of anergy. However, when high-dose CsA 
treatment  was temporarily interrupted,  e.g., at days 0 and 
1,  mice  had  an  intermediate  extent  of  deletion  of 
CD4 +/V36 + T cells (Table 1) and stronger in vitro prolifer- 
ative responses to Mls-1  a stimulation (Fig. 4 b, CsA/MIs*). 
It appears that in the latter case CsA had prevented anergy, 
while causing insufficient deletion to abrogate the prolifera- 
tive responses. 
Webb et al. (20) have reported that early after Mls-1" im- 
munization,  the CD4 +/V36 + T cells had a strong prolifer- 
ative response to Mls-1 a, but the peak response was seen at 
day 3 of in vitro cultures rather than day 4 for normal (un- 
treated) mice. However, this form of accelerated kinetics is 
not observed at day 14 postimmunization  (Fig.  5 B, and ref- 
erence 20), at which time the maximal proliferative response 
is weak. Accordingly, in CsA- and non-CsA-treated groups, 
we find that  the maximal proliferative responses at day 14 
post-Mls-1 ~ immunization  and at day 22 post-SEB immu- 
nization occur as with usual proliferative kinetics (day 4 peak) 
(Fig.  5).  SuperAg-immunized  mice (non-CsA  treated) had 
low peak responses despite the presence of substantial numbers 
of  potentially  Mls-l'-reactive  (CD4+/V/~6 +)  and  SEB- 
reactive  (CD4+/V/J8 §  T  cells,  and  these T  cells  can be 
markedly reduced in numbers by CsA treatment  (Tables  1 
and 2). 
Discussion 
This study was prompted by the numerous reports showing 
that CsA can alter immunologic tolerance (1, 8). These effects 
are poorly understood and often contradictory, since in some 
cases a short course of CsA treatment has induced tolerance 
to allografts, while in other experimental models this drug 
has provoked autoimmune phenomena (8). Enhanced toler- 
ance has  often been attributed  to the action  of suppressor 
cells (5,  7), while the paradoxical induction of autoimmune 
diseases has been imputed to defective thymocytic differenti- 
ation (9, 10). Nevertheless, for a variety of reasons, we hypothe- 
sized that CsA could also act by affecting peripheral  T  cell 
tolerance mechanisms (i.e., peripheral deletion and anergy). 
Our  study shows that  CsA treatment  can markedly en- 
hance  the  deletion  of superAg-reactive  T  ceils  in  either 
Mls-1 ~- or SEB-immunized mice. Without CsA treatment, 
the partial T cell elimination observed in superAg-immunized 
mice is limited and preceded by an expansion of the targeted 
T cells (19, 20, and our unpublished observations). Not sur- 
prisingly,  CsA prevents this expansion phase.  Nonetheless, 
the CsA/superAg-induced deletion occurs earlier and is more 
extensive than with superAg immunization alone.  Under op- 
timal  conditions,  the  extent  of  T  cell  elimination  in 
CsA/superAg-treated mice can vary from three- to fourfold 
greater than in non-CsA-treated  superAg-immunized  mice. 
In mice receiving CsA, up to 90% of reactive CD4 + T cells 
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results in an earlier and more extensive deletion process, seen 
at the time when donal expansion is often apparent in con- 
trol superAg-immunized mice. 
A combined CsA and superAg treatment had no effect on 
effect on nonreactive T cell V/~ subpopulations,  other than 
a slight increase in their frequencies, which likely resulted 
from the loss of the targeted subsets. Thus, CsA appears to 
enhance the deletion of only those T cells that are responding 
to superAgs. No sign of downmodulation of the TCR was 
detected,  and the cessation of CsA administration did not 
result in a rapid increase in the frequency of reactive T cells. 
In addition, in the Mls-la-injected groups (i.e., Mls-P alone 
or CsA/Mls-P), we found no detectable levels of donor T 
cells in the lymph nodes or the spleen. This excludes the pos- 
sibility of a massive expansion of non-V/~6  + donor T cells 
that could reduce the relative frequency of the host T  cell 
VB + subpopulations.  In view of these results, we believe 
that  the  disappearance  of  superAg-reactive  T  cells  in 
CsA/superAg-treated  mice results primarily from a deletion 
event rather than an alternative process. 
The deletion observed in Tx mice treated with CsA and 
Mls-1  a+ cells was similar to that of euthymic mice. There- 
fore, the CsAAuperAg-induced  T cell deletion is a periph- 
eral event, as reported by others in non-CsA-treated superAg- 
immunized mice (19, 20). 
The T cells of superAg-immunized  mice usually display 
a markedly reduced in vitro proliferative response to the same 
superAg (16-18). This condition is generally referred to as 
anergy. Recently, some authors have questioned the anergic 
status  of VB6 + T  cells in  Mls-P-immunized mice (20). 
They showed that early after immunization with Mls-1  a+ 
cells, the low responses to Mls-P were due to the different 
kinetics of responses in these mice (i.e., previously activated 
T cells had an earlier peak proliferative response). At day 14 
postimmunization, they observed (as we do) low prolifera- 
tive responses in Mls-1  '+ cells with no accelerated kinetics 
effect. They attributed the loss of strong in vitro prolifera- 
tive responses to the partial elimination of superAg-reactive 
T cells. However, our results do not support this conclusion, 
since  there  were  substantial  numbers  of  undeleted 
CD4 §  + T  cells at day 14 post-Mls-1  ~ immunization 
(without CsA) that could be markedly reduced by CsA treat- 
ment. Therefore, we conclude that most of the unresponsive 
CD4 +/VB6 + T cells of Mls-P-immunized mice (non-CsA 
treated) must be potentially Mls-P reactive since their dele- 
tion is specifically provoked by CsA,  as well as that these 
T  cells are anergic. 
Similarly, our results provide strong evidence that most 
of the nonresponsive V~8 + T cells of SEB-immunized mice 
are in fact TCR-SEB specific, since they can be specifically 
deleted with CsA treatment. Moreover, mice treated with 
CsA (50 mg/kg/d) and injected with SEB twice have a two- 
fold greater deletion of VB8 + T  cells vs. non-CsA-treated 
mice, but much higher in vitro proliferative responses to this 
superAg. Thus, the undeleted cells are superAg reactive, but 
fail to develop anergy in CsA-treated mice, The potential su- 
perAg reactivity of the majority of unresponsive Vfl6 § T 
cells (Mls-la-immunized  mice)  and unresponsive Vfl8 + T 
cells (SEB-immunized mice) has not been previously demon- 
strated.  In addition,  it is not unlikely that some of the re- 
sidual (undeleted) T cells are not superAg specific. However, 
if this is the case, such nonspecific  cells would represent <10% 
of all CD4+/Vfl6 + and CD4+/Vfl8 + T cells, based on the 
percent of cells that resist deletion. In accordance with our 
results, Rellahan et al. (18) found that the T cells of SEB- 
immunized mice proliferated only weakly when stimulated 
with an anti-Vfl8-mAb; i.e., there was no evidence of large 
numbers of nonanergic Vfl8 + T  cells. 
CsA clearly prevents the development of anergy in SEB- 
treated mice. However, this is only apparent in mice that have 
moderate deletion of CD4 +/Vfl8 + T  cells, as in mice in- 
jected with SEB only once. In mice with severe deletion of 
CD4+/Vfl8 + T  cells, e.g.,  mice injected  five times  with 
SEB, the in vitro proliferative responses to this superAg are 
very low. This indicates that extensive deletion of reactive 
T cells can counteract the strong in vitro proliferative  responses 
due to the blockage of anergy by CsA. This is also true in 
the case of Mls-P-immunized mice. Our results show that 
lower doses of CsA are required to prevent anergy induction 
than to enhance T cell deletion. This explains why mice in- 
jected with low doses of CsA had consistently higher in vitro 
proliferative responses to superAg than control mice (superAg 
immunized). 
The mechanism(s) by which CsA can prevent the induc- 
tion of anergy is not dear. CsA is known to block a Ca  2+- 
mediated T  cell activation pathway (28-30).  Interestingly, 
Mueller  et aL and Jenkins et al. (31, 32) have shown that 
the induction of anergy in CD4 +/Thl-type T cell clones de- 
pends on a Ca2+-mediated signal. CsA could prevent the in- 
duction of anergy in these clones (33). This raises the possi- 
bility that CsA may inhibit anergy induction in vivo by altering 
a  Ca2+-dependent  signal.  However,  the  mechanisms  of 
anergy induction in superAg-immunized mice are poorly un- 
derstood,  and our study did not address how CsA acts in 
this process. 
The work of Shiet al. (34) demonstrates that CsA blocks 
anti-CD3-induced programmed cell death (apoptosis) in the 
thymus. However, CsA does not prevent radiation-induced 
apoptosis in mature T  cells (35). Nevertheless, it was sur- 
prising to find that CsA could enhance peripheral T cell de- 
letion. One possibility is that peripheral T cells are not elim- 
inated by apoptosis, but the recent studies of Kawabe and 
Ochi (19) suggest that SEB may induce peripheral T cell apop- 
tosis. Interestingly, we found that the stimulation of T cells 
in vitro with matrix-bound anti-VB8 antibodies in the pres- 
ence of CsA induces specific death (within 72 h) of these 
cells, apparently by apoptosis (our unpublished observation). 
These preliminary data suggest that CsA may enhance apop- 
tosis in mature antigen-reactive T  cells. 
We can only speculate on the mechanism by which CsA 
enhances peripheral deletion, but Duke and Cohen (36) have 
shown that Ib2 deprivation  of activated T  cells results in 
death by apoptosis, Since CsA blocks Ib2 production (2-4) 
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ticle), the T cells activated by superAgs may be left with no 
source of Ib2.  This could possibly result in apoptosis and 
loss of reactive T  cells  in CsA/superAg-treated  mice. 
CsA/antigen-induced elimination of T cells may represent 
a mechanism of tolerance to allografts. CsA has been shown 
to induce long-term nonimmunosuppressed tolerance to al- 
lografts in many species  (37).  This occurs, for example, in 
rats pretreated with CsA and donor-specific blood transfu- 
sion before allograft transplantation (6). Tolerance to allografts 
has usually been attributed to antigen-specific  suppressor cells 
(5, 7). However, in accordance with our findings with su- 
perAg,  a recent study with limiting  dilution  analysis  sug- 
gests that CsA may induce tolerance to allografts by provoking 
the elimination of graft-reactive T  cells (38). On the other 
hand, since CsA blocks anergy it is possible that if the condi- 
tions of treatment used do not favor an extensive T cell dele- 
tion, then CsA may actually enhance immune responses and 
cause adverse effects.  In fact, CsA was shown to aggravate 
some autoimmune diseases, and to sometimes induce specific 
form of autoimmunity (reviewed in reference 8). CsA-induced 
syngeneic (or autologous) GVHD, in particular, has been ex- 
tensively studied (39-43). This condition occurs after with- 
drawal of CsA,  and is dearly an autoimmune disease that 
can be adoptively transferred with T cells. Some investigators 
have suggested that  this disease is due to a blockage of in- 
trathymic donal deletion in CsA-treated mice (9, 10), resulting 
in the production of autoaggressive T cells. However, we (11) 
and others (12) did not detect elevated numbers of peripheral 
forbidden (superAg-reactive)  T cells in mice with CsA-induced 
syngeneic GVHD. In fact, based in our current study, it is 
possible that even if such T  cell clones were not deleted in 
the thymus,  they would be at least partially deleted in the 
periphery under the influence of CsA. However, as shown 
by our results, CsA does not necessarily induce a complete 
deletion of superAg-reactive T cells. For example, CsA-treated 
mice receiving only one injection of SEB had a moderate de- 
letion of CD4 +/VB8 + T  cells,  and had enhanced in vitro 
responses to SEB compared with non-CsA-treated controls. 
Several SEB injections were required to induce a maximal T 
cell deletion. Similarly, low doses of CsA blocked anergy in- 
duction, but did not enhance clonal deletion.  Conceivably, 
since CsA blocks anergy, this drug could induce autoimmune 
states or aggravate autoimmune diseases in cases where there 
is only a low or moderate deletion of autoaggressive T cells 
and a blockage of anergy induction. In CsA-induced syngeneic 
GVHD, the effector T  cells may consist of T  cells that  are 
normally tolerized primarily by anergy rather than intrathymic 
deletion. This hypothesis is consistent with the observation 
that in some mouse strains CsA treatment induces this disease, 
despite apparently normal intrathymic clonal deletion (12). 
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